---
schema_version: "secwatch.filing_event.v1"
accession: "0001672688-26-000086"
form_type: "8-K"
ticker: "ABSI"
cik: "0001672688"
company_name: "Absci Corp"
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:50:40.831028+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Absci completes all SAD cohorts of ABS-201, initiates MAD; Q1 net loss $29.6M

## Summary
- Successfully dosed all four SAD cohorts of ABS-201 Phase 1/2a; well-tolerated with favorable safety.
- Initiated MAD dosing in AGA participants; preliminary PK supports 2-3 injections over six months.
- Expanded pipeline with ABS-202, a novel anti-PRLR antibody for undisclosed I&I indication.
- Q1 revenue $0.2M, net loss $29.6M; cash $125.7M sufficient into first half of 2028.
- Anticipates reporting preliminary safety, tolerability, PK data in Q2 2026; proof-of-concept in H2 2026.

## SEC filing metadata
- accession: 0001672688-26-000086
- form_type: 8-K
- ticker: ABSI
- cik: 0001672688
- company_name: Absci Corp
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672688/000167268826000086/0001672688-26-000086-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672688/000167268826000086/absc-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001672688-26-000086
- JSON: https://secwatch.observer/filing/0001672688-26-000086.json
- Plain text: https://secwatch.observer/filing/0001672688-26-000086.txt

## Source-grounded claims
- claim_id: c3471be34d470dd8d9562e6c3cf0e636bcf55b59
  claim: Absci Corp reported first quarter ended March 31, 2026 results: revenue $0.2 million.
  evidence_excerpt: Revenue was $0.2 million for the three months ended March 31, 2026, compared to $1.2 million for the three months ended March 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1672688/000167268826000086/0001672688-26-000086-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.